Melbourne. Australia

November 27, 2023
Published by admin on November 27, 2023
Categories

Mr Roger McPherson appointed CFO / Company Secretary
27 Nov 2023

OBM is delighted to welcome Roger to the executive team. He brings significant technical skill and industry experience to the company. Roger has more than 30 […]
Do you like it?8
0 Read more
November 1, 2023
Published by admin on November 1, 2023
Categories

AusBiotech conference Brisbane
1 – 3 Nov 2023

OBM recently attended Australias premier biotechnology conference in Brisbane – represented by CEO Andrew Coloretti & Non-Executive Director Michelle Gallaher. The conference included valuable one-on-one private […]
Do you like it?7
0 Read more
October 9, 2023
Published by admin on October 9, 2023
Categories

Oculus BioMed Limited partners with The Centre for Eye Research Australia (CERA) in a deal to develop “SwitchGene” – Eye Gene therapies.
11 Oct 2023

Oculus BioMed (OBM) an ophthalmology focused biotechnology company, entered into a collaboration agreement with CERA – Centre for Eye Research Australia regarding the development of a therapeutic […]
Do you like it?4
0 Read more
October 1, 2023
Published by admin on October 1, 2023
Categories

Ms Michelle Gallaher appointed Non-Executive Director
01 Oct 2023

OBM is delighted to welcome Michelle to the Board. She is an exceptional person and professional and brings significant industry experience and skill to the company. […]
Do you like it?4
0 Read more
July 1, 2023
Published by admin on July 1, 2023
Categories

Professor Robyn Guymer AM appointed to OBM Scientific Board
1st July 2023

We are delighted to welcome Robyn to the OBM Scientific Board. She brings significant experience and currency to the company. Background profile follows: Professor Robyn Guymer […]
Do you like it?2
0 Read more
February 22, 2022
Published by admin on February 22, 2022
Categories

Melbourne, Australia;
22 February 2022 – Research Data Which Covers OBM’s OBM-1701 for the Treatment of wet-AMD Has Been Published on a Prominent Peer-reviewed Journal

Oculus Biomed Limited (“OBM”) is pleased to announce that the research data which covers OBM’s OBM-1701, its leading drug candidate for the treatment of wet-AMD, has […]
Do you like it?17
0 Read more
October 5, 2021
Published by admin on October 5, 2021
Categories

Melbourne, Australia;
05 October 2021 – OBM Enters R&D Agreement with Centre for Eye Research Australia (“CERA”)

Oculus Biomed Limited (“OBM”) is pleased to announce that it has entered an Agreement with Centre for Eye Research Australia (“CERA”), in Melbourne, Victoria State, Australia. […]
Do you like it?17
0 Read more
June 11, 2021
Published by admin on June 11, 2021
Categories

Melbourne, Australia;
11 June 2021 – Key Chinese Patent covering OBM-1701 Granted

Oculus Biomed Limited (“OBM”) is pleased to announce the grant of the Chinese Patent which covers the OBM-1701, OBM’s leading novel drug candidate for treating wet-type […]
Do you like it?17
0 Read more
June 2, 2021
Published by admin on June 2, 2021
Categories

Melbourne, Australia;
2 June 2021 – Key EU Patent covering OBM-1701 Granted

Oculus Biomed Limited (“OBM”) is pleased to announce the European patent application which covers the OBM-1701, OBM’s leading novel drug candidate for treating wet-type age-related macular […]
Do you like it?14
0 Read more
12
Next page